NCT05925920View on ClinicalTrials.gov

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

August 12, 2024

Study Completion Date

December 6, 2024

Conditions

ObesityDiabetes Mellitus, Type 2

Interventions

DRUG

ENT-03

single dose of active drug

DRUG

Placebo

single dose of placebo comparator

Trial Locations (1)

91911

ProSciento, San Diego

Sponsors

Lead Sponsor

Metabolics Pharma

All Listed Sponsors

lead

Metabolics Pharma

INDUSTRY

NCT05925920 - Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes | Biotech Hunter | Biotech Hunter